Avantis核心固定收益主动型ETF AVIG 深 沪
等待开盘 05-21 09:30:00 美东时间
41.12
+0.250
+0.61%
华盛通- 最 高41.15
- 今 开40.87
- 成交量 15.08万股
- 最 低 40.87
- 昨 收 40.87
- 总市值 180.11万
- 52周最高 42.1007
- 市盈率 静 --
- 换手率 344.36%
- 52周最低 39.0793
- 委 比 20.00%
- 总股本 4.38万
- 历史最高 42.8258
- 量 比 0.73
- 振 幅 0.69%
- 历史最低 33.0575
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Regenxbio Q1 FY26 net loss widens to $90.05 million; revenue drops 92.82% to $6.39 million
Regenxbio Q1 FY26 net loss widens to $90.05 million; revenue drops 92.82% to $6.39 million Regenxbio posted a net loss of USD 90.05 million, swinging from net income of USD 6.08 million a year earlier, as revenue fell 92.83% to USD 6.39 million. Operating loss widened to USD 83.36 million from opera
05-14 19:32
BRIEF-Aramco East-West Pipeline Sharply Ramped Up To Reach Its Maximum Capacity Of 7.0 Mln BPD In Q1
BRIEF-Aramco East-West Pipeline Sharply Ramped Up To Reach Its Maximum Capacity Of 7.0 Mln BPD In Q1 May 10 (Reuters) - Saudi Arabian Oil Co 2222.SE : SAUDI ARAMCO - EAST-WEST PIPELINE, HELPING TO MITIGATE IMPACT OF GLOBAL ENERGY SHOCK SAUDI ARAMCO - EAST-WEST PIPELINE, PROVIDING RELIEF TO CUSTOMERS
05-10 13:05
BRIEF-Navigator Gas Signs LoI For Sale Of Eight Gas Vessels And Its Shareholding In Unigas Joint Venture For $183 Million
BRIEF-Navigator Gas Signs LoI For Sale Of Eight Gas Vessels And Its Shareholding In Unigas Joint Venture For $183 Million April 15 (Reuters) - Navigator Holdings Ltd 1NV.F : NAVIGATOR GAS ANNOUNCES SIGNING OF NON-BINDING LETTER OF INTENT FOR SALE OF EIGHT GAS VESSELS AND ITS SHAREHOLDING IN UNIGAS J
04-15 14:03
ROI-Iran's Hormuz 'toll booth' set to hardwire higher energy prices: Bousso
ROI-Iran's Hormuz 'toll booth' set to hardwire higher energy prices: Bousso The opinions expressed here are those of the author , a columnist for Reuters By Ron Bousso LONDON, April 9 (Reuters) - The war that closed the Strait of Hormuz has ended - for now. But Tehran's demand to act as toll booth k
04-09 08:01
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs Overview U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027 Outlook Company expe
03-31 20:09
BRIEF-Koninklijke Philips Receives FDA Gives 510(K) Clearance For EchoNavigator R5.0 With DeviceGuide
BRIEF-Koninklijke Philips Receives FDA Gives 510(K) Clearance For EchoNavigator R5.0 With DeviceGuide March 26 (Reuters) - Koninklijke Philips NV PHG.AS : FDA GIVES 510(K) CLEARANCE FOR ECHONAVIGATOR R5.0 WITH DEVICEGUIDE Source text: here Further company coverage: PHG.AS (Gdansk Newsroom) (( gdansk
03-26 21:12
BRIEF-Xona Closes $170M Series C To Lead Next Era Of Global Navigation
BRIEF-Xona Closes $170M Series C To Lead Next Era Of Global Navigation XONA CLOSES $170M SERIES C TO LEAD NEXT ERA OF GLOBAL NAVIGATION XONA: SERIES C FUNDING ROUND LED BY MOHARI VENTURES NATURAL CAPITAL Source text: ID:nBw2PQTzHa Further company coverage: [ ]
03-26 20:52
BRIEF-Delta Air Lines Raises Q1 Revenue Guidance On Accelerated Demand Trends In March
BRIEF-Delta Air Lines Raises Q1 Revenue Guidance On Accelerated Demand Trends In March March 17 (Reuters) - Delta Air Lines Inc DAL.N : DELTA AIR LINES INC- RAISES Q1 REVENUE GUIDANCE ON ACCELERATED DEMAND TRENDS IN MARCH - SEC FILING DELTA AIR LINES INC: EXPECT MARCH QUARTER EARNINGS WITHIN INITIAL
03-17 18:53
BRIEF-Ten, Ltd. Reports Profits For The Twelve-Months And Fourth Quarter Ended December 31, 2025
BRIEF-Ten, Ltd. Reports Profits For The Twelve-Months And Fourth Quarter Ended December 31, 2025 March 6 (Reuters) - Tsakos Energy Navigation Ltd TEN.N : TEN, LTD. REPORTS PROFITS FOR THE TWELVE-MONTHS AND FOURTH QUARTER ENDED DECEMBER 31, 2025 TSAKOS ENERGY NAVIGATION LTD QTRLY GROSS REVENUES $222.
03-06 21:56
Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million
Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million REGENXBIO reported Q4 2025 total revenues of USD 30.3 million and a net loss of USD 67.1 million, or USD 1.30 per share. For FY 2025, total revenues were USD 170.4 million and net loss was USD 193.9 million, or USD 3.76 per share. R&D expenses
03-05 20:06
